InChI=1S/C29H41NO4/c1- 25(2,3) 26(4,32) 20- 15- 27- 10- 11- 29(20,33- 5) 24- 28(27) 12- 13- 30(16- 17- 6- 7- 17) 21(27) 14- 18- 8- 9- 19(31) 23(34- 24) 22(18) 28/h8- 9,17,20- 21,24,31- 32H,6- 7,10- 16H2,1- 5H3/t20- ,21- ,24- ,26+,27- ,28+,29- /m1/s1 |
RMRJXGBAOAMLHD-IHFGGWKQSA-N |
[H][C@@]1(C[C@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5C[C@H]2N(CC[C@@]31c45)CC1CC1)[C@](C)(O)C(C)(C)C |
|
kappa-opioid receptor antagonist
Any compound that exhibits antagonist activity at the kappa-opioid receptor.
opioid analgesic
A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonist
A compound that exhibits agonist activity at the mu-opioid receptor.
delta-opioid receptor antagonist
Any compound that exhibits antagonist activity at the delta-opioid receptor.
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via alkaloid )
|
|
kappa-opioid receptor antagonist
Any compound that exhibits antagonist activity at the kappa-opioid receptor.
opioid analgesic
A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonist
A compound that exhibits agonist activity at the mu-opioid receptor.
delta-opioid receptor antagonist
Any compound that exhibits antagonist activity at the delta-opioid receptor.
|
|
View more via ChEBI Ontology
(5α,6β,14β,18R)- 17- (cyclopropylmethyl)- 18- [(2S)- 2- hydroxy- 3,3- dimethylbutan- 2- yl]- 6- methoxy- 18,19- dihydro- 4,5- epoxy- 6,14- ethenomorphinan- 3- ol
|
buprenorfina
|
ChemIDplus
|
buprenorphine
|
ChemIDplus
|
buprenorphinum
|
ChemIDplus
|
(−)-buprenorphine
|
ChEBI
|
17- cyclopropylmethyl- 4,5α- epoxy- 7α- ((S)- 1- hydroxy- 1,2,2- trimethylpropyl)- 6- methoxy- 6,14- endo- ethanomorphinan- 3- ol
|
ChemIDplus
|
2- (N- cyclopropylmethyl- 4,5α- epoxy- 3- hydroxy- 6- methoxy- 6,14- endo- ethanomorphinan- 6α- yl)- 3,3- dimethyl- 2- butanol
|
ChemIDplus
|
2- [3- cyclopropylmethyl- 11- hydroxy- 15- methoxy- (14R)- 13- oxa- 3- azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa- 7,9,11- trien- 16- yl]- 3,3- dimethyl- 2- butanol
|
ChEMBL
|
21- cyclopropyl- 7α- [(S)- 1- hydroxy- 1,2,2- trimethylpropyl]- 6,14- endo- ethano- 6,7,8,14- tetrahydrooripavine
|
ChemIDplus
|
Buprenorphine
|
KEGG COMPOUND
|
1789
|
VSDB
|
434
|
DrugCentral
|
559124
|
ChemSpider
|
Buprenorphine
|
Wikipedia
|
C08007
|
KEGG COMPOUND
|
CPD-22086
|
MetaCyc
|
D07132
|
KEGG DRUG
|
DB00921
|
DrugBank
|
GB1136214
|
Patent
|
HMDB0015057
|
HMDB
|
US3433791
|
Patent
|
View more database links |
52485-79-7
|
CAS Registry Number
|
KEGG COMPOUND
|
52485-79-7
|
CAS Registry Number
|
ChemIDplus
|
52485-79-7
|
CAS Registry Number
|
NIST Chemistry WebBook
|
6182863
|
Beilstein Registry Number
|
Beilstein
|
10649968
|
PubMed citation
|
ChEMBL
|
11303059
|
PubMed citation
|
Europe PMC
|
15181649
|
PubMed citation
|
Europe PMC
|
15781180
|
PubMed citation
|
Europe PMC
|
16642964
|
PubMed citation
|
Europe PMC
|
16650985
|
PubMed citation
|
ChEMBL
|
17887741
|
PubMed citation
|
ChEMBL
|
18997874
|
PubMed citation
|
Europe PMC
|
19402772
|
PubMed citation
|
Europe PMC
|
32925232
|
PubMed citation
|
Europe PMC
|
33378137
|
PubMed citation
|
Europe PMC
|
PMC7711199
|
PubMed Central citation
|
Europe PMC
|
|